A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy

Biomaterials

Volumn 33, Issue 1, 2012, Pages 146-162

  Shan, Lingling ^a,b   Cui, Sisi ^a   Du, Changli ^a   Wan, Shunan ^a   Qian, Zhiyu ^c   Achilefu, Samuel ^d   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b SUZHOU UNIVERSITY   (China)

^c NANJING UNIVERSITY OF AERONAUTICS AND ASTRONAUTICS   (China)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Adenovirus; Paclitaxel; Prodrug; Targeting; Therapy effect

Indexed keywords

ADENOVIRUS; PACLITAXEL; PRODRUGS; TARGETING; THERAPY EFFECT;

DRUG DELIVERY; FLUORESCENCE; INFRARED DEVICES; TOXICITY;

TUMORS;

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; FLUORESCENT DYE; FOLIC ACID; NANOPARTICLE; PACLITAXEL; PRODRUG; SUCCINIC ANHYDRIDE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; PACLITAXEL; RECEPTORS, VIRUS;

ADENOVIRIDAE; MUS;

EID: 82855172119     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.09.025     Document Type: Article

References (39)

1. Xin H., Jiang X., Gu J., Sha X., Chen L., Law K., et al. Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32:4293-4305.
2. Lin Y.S., Tungpradit R., Sinchaikul S., An F.M., Liu D.Z., Phutrakul S., et al. Targeting the delivery of glycan-based paclitaxel prodrugs to cancer cells via glucose transporters. J Med Chem 2008, 51:7428-7441.
3. Elsadek B., Graeser R., Esser N., Schäfer-Obodozie C., Ajaj K.A., Unger C., et al. Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study. Eur J Cancer 2010, 46:3434-3444.
4. Shahin M., Ahmed S., Kaur K., Lavasanifar A. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel. Biomaterials 2011, 32:5123-5133.
5. Musacchio T., Laquintana V., Latrofa A., Trapani G., Torchilin V.P. PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm 2009, 6:468-479.
6. McConnell M.J., Imperiale M.J. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004, 15:1022-1033.
7. Ewert K., Slack N.L., Ahmad A., Evans H.M., Lin A.J., Samuel C.E., Safinya C.R. Cationic lipid-DNA complexes for gene therapy: understanding the relationship between complex structure and gene delivery pathways at the molecular level. Curr Med Chem 2004, 11:133-149.
8. Warren J.C., Rutkowski A., Cassimeris L. Infection with replication-deficient adenovirus induces changes in the dynamic instability of host cell microtubules. Mol Biol Cell 2006, 17:3557-3568.
9. Anderson E.A., Isaacman S., Peabody D.S., Wang E.Y., Canary J.W., Kirshenbaum K. Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett 2006, 6:1160-1164.
10. Allen M., Bulte J.W., Liepold L., Basu G., Zywicke H.A., Frank J.A., et al. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 2005, 54:807-812.
11. Adam J.F., Biston M.C., Rousseau J., Boudou C., Charvet A.M., Balosso J., et al. Heavy element enhanced synchrotron stereotactic radiotherapy as a promising brain tumor treatment. Phys Med 2008, 24:92-97.
12. Shan L., Xue J., Guo J., Qian Z., Achilefu S., Gu Y. Improved targeting of ligand-modified adenovirus as a new near infrared fluorescence tumor imaging probe. Bioconjug Chem 2011, 22:567-581.
13. Michaud L.B., Valero V., Hortobagyi G. Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 2000, 23:401-428.
14. Lichtman S.M., Hurria A., Cirrincione C.T., Seidman A.D., Winer E., Hudis C., et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2011 Jun 21, [Epub ahead of print].
15. Lee J., Lee S.C., Acharya G., Chang C.J., Park K. Hydrotropic solubilization of paclitaxel: analysis of chemical structures for hydrotropic property. Pharm Res 2003, 20:1022-1030.
16. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
17. Kratz F., Abu Ajaj K., Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 2007, 16:1037-1058.
18. Ajaj K.A., Biniossek M.L., Kratz F. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs. Bioconjug Chem 2009, 20:390-396.
19. Ryppa C., Mann-Steinberg H., Biniossek M.L., Satchi-Fainaro R., Kratz F. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3. Int J Pharm 2009, 368:89-97.
20. Ingemarsdotter C.K., Baird S.K., Connell C.M., öberg D., Halldén G., McNeish I.A. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene 2010, 29:6051-6063.
21. Nielsen L.L., Lipari P., Dell J., Gurnani M., Hajian G. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer. Clin Cancer Res 1998, 4:835-846.
22. Lee E., Lee J., Lee I.H., Yu M., Kim H., Chae S.Y., et al. Conjugated chitosan as a novel platform for oral delivery of paclitaxel. J Med Chem 2008, 51:6442-6449.
23. Oh I.K., Mok H., Park T.G. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells. Bioconjug Chem 2006, 17:721-727.
24. Mueller H., Kassack M.U., Wiese M. Comparison of the usefulness of the MTT, ATP, and calcein assays to predict the potency of cytotoxic agents in various human cancer cell lines. J Biomol Screen 2004, 9:506-515.
25. Chen S., Cheng A.C., Wang M.S., Peng X. Detection of apoptosis induced by new type gosling viral enteritis virus in vitro through fluorescein annexin V-FITC/PI double labeling. World J Gastroenterol 2008, 14:2174-2178.
26. Eray M., Mättö M., Kaartinen M., Andersson L., Pelkonen J. Flow cytometric analysis of apoptotic subpopulations with a combination of annexin V-FITC, propidium iodide, and SYTO 17. Cytometry 2001, 43:134-142.
27. Liu F., Deng D., Chen X., Qian Z., Achilefu S., Gu Y. Folate-polyethylene glycol conjugated near-infrared fluorescence probe with high targeting affinity and sensitivity for in vivo early tumor diagnosis. Mol Imaging Biol 2010, 12:595-607.
28. Gao J., Chen K., Xie R., Xie J., Yan Y., Cheng Z., et al. In vivo tumor-targeted fluorescence imaging using near-infrared of non-cadmium quantum dots. Bioconjug Chem 2010, 21:604-609.
29. Cheng Z., Wu Y., Xiong Z., Gambhir S.S., Chen X. Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 2005, 16:1433-1441.
30. Span L.F., Pennings A.H., Vierwinden G., Boezeman J.B., Raymakers R.A., de Witte T. The dynamic process of apoptosis analyzed by flow cytometry using Annexin-V/propidium iodide and a modified in situ end labeling technique. Cytometry 2002, 47:24-31.
31. Wall M.E. Camptothecin and taxol: discovery to clinic. Med Res Rev 1998, 18:299-314.
32. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
33. Nieto Y., Cagnoni P.J., Bearman S.I., Shpall E.J., Matthes S., DeBoom T., et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res 1999, 5:501-506.
34. Scuteri A., Nicolini G., Miloso M., Bossi M., Cavaletti G., Windebank A.J., et al. Paclitaxel toxicity in post-mitotic dorsal root ganglion (DRG) cells. Anticancer Res 2006, 26:1065-1070.
35. Desai P.B., Duan J.Z., Zhu Y.W., Kouzi S. Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 1998, 23:417-424.
36. Panday V.R., Huizing M.T., Willemse P.H., De Graeff A., ten Bokkel Huinink W.W., Vermorken J.B., et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997, 24. S11-34-S11-38.
37. Zhang J., Deng D., Qian Z., Liu F., Chen X., An L., et al. The targeting behavior of folate-nanohydrogel evaluated by near infrared imaging system in tumor-bearing mouse model. Pharm Res 2010, 27:46-55.
38. Zhang J., Chen H., Xu L., Gu Y. The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model. J Control Release 2008, 131:34-40.
39. Chen H., Wang Y., Xu J., Ji J., Zhang J., Hu Y., et al. Non-invasive near infrared fluorescence imaging of CdHgTe quantum dots in mouse model. J Fluoresc 2008, 18:801-811.